#ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEY

ESMO - Eur. Oncology· @myESMO · X·2026-10-24 14:30· 1 day agoScore70

Body · original

#ESMO26: Pembrolizumab plus chemotherapy reduced the risk of PFS by 26% in PD-L1-positive, HR-positive #AdvancedBreastCancer after failure on endocrine therapy in the phase III KEYNOTE-B49

🔗 https://ow.ly/5NoZ50ZZjCH

#ClinicalTrial #BreastCancer #InsightsbyESMO
@PTarantinoMD

302 views · 1 like · 0 reposts · 0 replies

Conference abstracts

LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage

Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)

https://esmocongress.esmo.org

Source: ESMO - Eur. Oncology · x.com